17053-73-5

Basic information

• Product Name: Arsonic acid, [4-(1H-purin-6-ylamino)phenyl]-
• CAS NO: 17053-73-5
• Molecular Formula: C11H10AsN5O3
• Molecular Weight: 335.154
• Mol File: 17053-73-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Arsonic acid, [4-(1H-purin-6-ylamino)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Arsonic acid, [4-(1H-purin-6-ylamino)phenyl]-(17053-73-5)
• EPA Substance Registry System: Arsonic acid, [4-(1H-purin-6-ylamino)phenyl]-(17053-73-5)

Safety Data

• Hazardous Substances Data: 17053-73-5(Hazardous Substances Data)

Upstream product

• 98-50-0 p-aminophenylarsonic acid 
• 87-42-3 6-chloropurine 

Relevant articles and documents

Organic phenyl arsonic acid compounds with potent antileukemic activity

A series of 12 organic arsonic acid compounds has been synthesized and evaluated against human B-lineage (NALM-6) and T-lineage (MOLT-3) acute lymphoblastic leukemia (ALL) cell lines. The lead compounds 2-trichloromethyl-4-[4′-(4″-phenylazo)phenylarsonic acid]aminoquinazoline (compound 19, PHI-P518; IC50=1.1±0.5 μM against NALM-6 and 2.0±0.8 μM against MOLT-3) and 2-methylthio-4-(2′-phenylarsonic acid)aminopyrimidine (compound 15, PHI-P381; IC50=1.5±0.3 μM against NALM-6 and 2.3±0.5 μM against MOLT-3) exhibited potent antileukemic activity at low micromolar concentrations.

Phenylarsonic acid compounds with broad-spectrum and potent cytotoxic activity against human cancer cells

The in vitro cytotoxic activity profile of nine novel phenylarsonic acid (CAS 98-05-5, PAA) compounds against 17 human cancer cell lines including (a) ovarian cancer cell lines ES-2, PA-1, CAOV-3, OVCAR-3, (b) testicular cancer cell lines Ntera-2, Tera-2, N2NICP, 833K, and 64CP, (c) multiple myeloma cell lines ARH77, HS-Sultan, RPMI-8226, and U266, and (d) acute lymphoblastic leukemia (ALL) cell lines NALM-6, MOLT-3, ALL-1, and RS4; 11, was determined by the MTT assay. The lead compounds, 2-methylthio4- [(4′-aminophenylazo)-phenylarsonic acid] pyrimidine (PHI-370) and 2-methylthio-4-(4′-phenylarsonic acid)-aminopyrimidine (PHI-380) caused apoptotic death in all 17 cancer cell lines at low micromolar concentrations, as documented by TUNEL assays and confocal laser scanning microscopy. PHI-380 was also tested and found to be very active against primary tumor cells isolated from surgical biopsy specimens of 14 patients with therapy-refractory non-small cell lung cancer, breast cancer, colon cancer, lymphoma, hepatoblastoma, or Wilm's tumor as well. Because of their broad-spectrum and potent anticancer activity and ability to induce apoptosis in primary tumor cells from therapy-refractory cancer patients, PAA compounds such as PHI-370 and PHI-380 may provide the basis for effective salvage regimens for patients with recurrent cancer.